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Abstract. We studied the effects of cortisol withdrawal and
patterned replacement upon spontaneous GH secretion and
circadian rhythmicity in 7 patients with Addison’s disease.
Hydrocortisone was administered in physiological daily to-
tal dosages, and all resulting plasma cortisol values were
2–15 lg/dl. It was given in 3 pulsatile modes: simulating
“physiological” rhythm, “reverse” diurnal rhythmicity and
“continuous” pulsatility. All modes of cortisol administra-
tion increased mean 24h, GH pulse amplitude and inter-
pulse GH levels. During saline infusions circadian GH rhyth-
micity was preserved, with GH being at its highest between
2400–0400 h. Administration of hydrocortisone in any mode
did not modify circadian GH rhythmicity. We conclude: Cor-
tisol replacement in physiological daily doses increases GH
output in patients with Addison’s disease by augmenting GH
pulse amplitude and interpulse levels. This is likely due to
the attenuation of hypothalamic somatostatin (SRIF) se-
cretion by physiologic levels of cortisol. By inference, it
implies that cortisol deficiency leads to diminution of GH
output with low GH pulse amplitude, likely as a result of an
augmented hypothalamic somatostatin secretion. However,
circadian rhythmicity of GH secretion is glucocorticoid-in-
dependent.
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Introduction
Glucocorticoids exert powerful effects upon GH syn-
thesis and secretion. Alterations in GHRH and SRIF
mRNA’s expression [1,2], pituitary GHRH receptors
[3], GH gene expression [4] and GH release [5] have
been reported in vitro and in animals post adrenalec-
tomy or glucocorticoid administration. In humans, un-
derstandably, the information is not as detailed but GH
deficiency is a regular consequence of Cushing’s syn-
drome [6,7]. The effects of glucocorticoid deprivation in
humans are even less well studied. Isolated ACTH
deficiency is accompanied by diminished GH responses
to a variety of provocative stimuli and these are nor-
malized by glucocorticoid replacement [8,9].  On  the
other hand, a dose-dependent inhibition of the GHRH-
induced GH release has been observed in patients with
Addisons’s disease given short-term hydrocortisone in-
fusions [10].
The effects of chronic glucocorticoid deprivation
and/or  replacement upon  spontaneous GH secretion
have never been studied in humans. Also, the effects of
glucocorticoids upon circadian GH rhythm in humans
have not been examined. Interestingly, circadian
rhythms of GH and TSH are almost parallel, with rela-
tively low levels throughout the day and a temporary
augmentation during early night hours [11]. Since glu-
cocorticoids are believed to stimulate somatostatin
(SRIF) secretion [2], one can hypothesize that the cir-
cadian rhythm of cortisol secretion is the driving
mechanism for both TSH and  GH rhythms. In this
model, high morning cortisol levels increase SRIF se-
cretion which in turn suppresses both TSH and GH,
whereas a nocturnal decrease in cortisol suppresses
SRIF secretion with the resultant disinhibition of both
TSH and GH. If this hypothesis is correct, patients
with Addison’s disease should have enhanced daytime
TSH and GH release with absent or blunted circadian
rhythm and a “physiologic” cortisol replacement
should restore circadian TSH and GH rhythmicity and
attenuate daytime hormone release. This hypothesis is
supported by the existing data on TSH pulsatility: in
patients with Addison’s disease, daytime TSH levels
are tonically elevated, nocturnal rise of TSH is lost and
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replacement of cortisol in a physiological dose and pat-
tern (high morning and low nighttime levels) restores
normal circadian TSH rhythm [12]. However, the same
doses of cortisol given as a continuous infusion or in a
“reverse”  pattern (low  morning  and  high  nighttime
levels) are ineffective in this regard. These data sup-
port the model of glucocorticoid-dependent TSH
rhythmicity. To test whether it is also applicable to GH
rhythmicity, we conducted a study in 7 patients with
Addison’s disease. GH pulsatility and circadian rhyth-
micity were assessed both before and during cortisol
replacement given in different modes.
Subjects and Methods
Seven subjects (4 men, 3 women) with a long-standing
Addison’s disease were recruited for the study. Their
mean age was 42 years (range 29–67) and their mean
BMI was 29 kg/m2 (range 22–43). The protocol was
approved by the IRB at the Oregon Health Sciences
University and a written consent form was signed by
all subjects before entering the study. Clinical data and
detailed description of the protocol have been publish-
ed previously [12,13]. In brief, on four separate occa-
sions at least one month apart, the subjects were hos-
pitalized in the CRC at the Oregon Health Sciences
University. Regular hydrocortisone replacement was
stopped 24 hours prior to admission but other replace-
ments (Florinef in all, thyroxine in 2, estrogen/proges-
terone in two) were continued. Starting the next morn-
ing, either normal saline or hydrocortisone (19 mg/day)
were infused for 48 hrs. Hydrocortisone was given as
a.) 11 equal, 20 minute long infusions given at 130 min
intervals (“continuous”), b.) as patterned short-term
infusions to mimic the “physiological” rhythm, i.e. same
total dose and number of pulses as the “continuous”
study, but with the timing and variable pulse amplitude
designed to replicate normal 24h cortisol profiles; or c.)
as a “reverse” rhythm (same dose and number of
pulses but the diurnal rhythm reversed). The exact
schemata of different modes of hydrocortisone admini-
stration were shown in a previous publication [13]. In
two subjects, “physiological” and “reverse” studies
were done using 38 mg hydrocortisone per day, in or-
der to achieve normal cortisol levels as explained pre-
viously [13]. Blood sampling was done on the second
infusion day, for 24 hrs (0800–0800h) every 15 minutes.
Samples were initially assayed for cortisol, leptin, and
TSH and the results were already reported [12, 13].
After that, samples were transferred on dry ice to the
University of Michigan, and GH concentrations were
measured there. We utilized the chemiluminometric
GH assay (Nichols, San Juan Capristrano, CA) with
assay sensitivity 0.01 lg/L, intraassay variability
,10% in the relevant assay range and interassay vari-
ability ,10%. All samples from the same individual
were assayed in duplicate, in the same assay.
Analysis
Discrete parameters of GH pulsatility were assessed
by Cluster algorithm [14]. False-positive pulse detec-
tion was assumed when the program identified a pulse
with the amplitude ,0.03 lg/L (14). In 5 subjects, all
serum samples were available for the analysis. In 1
subject, 16 consecutive samples corresponding to
0400–0800h were missing from the baseline (saline) se-
ries. His pulse frequency was adjusted upward by 1/6,
and the 0400–0800h block was missing from the rhyth-
micity analysis (see below). In another subject, a total
of 26 samples were missing from the baseline series,
both nonconsecutively and in clusters. In this series,
we calculated mean GH concentrations only, but did
not perform evaluations of pulsatility or circadian
rhythmicity. To evaluate circadian GH rhythmicity, we
calculated mean GH concentrations in blocks
(0800–1145h; 1200–1545h . . . etc.), creating six 4-hour
blocks per each study. Area versus time curves (AUC)
for the 4-hour blocks were calculated using trapezoidal
rule. Data were analyzed by a repeated measures
ANOVA with subsequent Tukey-Kramer procedure.
The use of PROC. MIXED in SAS package allowed for
the use of sets with missing data. When the data were
not normally distributed, they were logarithmically
transformed prior to analysis. Statistical significance
was assumed at p , 0.05 level.
Results
Plasma cortisol (Figure 1)
During saline infusion all cortisol values were below 1
lg/dl. During “continuous” cortisol administration,
plasma cortisol concentrations fluctuated periodically,
between 6 and 12 lg/dl, as would be expected from 20
min long, Q130 min intravenous infusions. During
“physiological” patterned infusions, plasma cortisol
concentrations were  between  9  and  15 lg/dl in the
morning (peak between 0830 and 0930 h) and were low
(2–3 lg/dl) between 2200 and 0400 h. During the “re-
verse” study, plasma cortisol concentrations were at
10–14 lg/dl between 1830 and 0145h (peak at 2100h)
and were low (2–4 lg/dl) between 0915 and 1700 h. In
all samples plasma cortisol levels fluctuated within the
physiologic range observed in healthy humans, i.e.,
2–15 lg/dl.
Growth hormone
Examples of GH profiles in 2 subjects during all 4 steps
of the protocol are shown in Fig. 2. Discrete parame-
ters of GH pulsatility as defined by Cluster algorithm
are shown in Fig. 3. There was a significant increase in
mean GH concentrations between baseline (saline
study) and “physiological”/“reverse” cortisol infusion
studies (0.43 6 0.12 vs. 0.93 6 0.22 and 0.98 6 0.25 lg/L;
p 5 0.02). During “continuous” cortisol delivery,
plasma GH was 0.8 6 0.23 lg/L, with a trend toward
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increase vs. baseline (p 5 0.08). There was no differ-
ence in pulse frequency between all steps of the proto-
col. At baseline, mean GH pulse amplitude was 1.14 6
0.4 lg/L. It rose to 2.34 6 0.57 and 2.15 6 0.48 lg/L
during “physiological” and “reverse” cortisol infusions
(p 5 0.02). Again, there was only a trend toward pulse
amplitude increase during “continuous” cortisol deliv-
ery (p 5 0.11). The interpulse GH levels during the
baseline study (0.084 6 0.03 lg/L) increased threefold
during all cortisol infusions (0.24 6 0.05 lg/L for the
“continuous”, 0.235 6 0.06 lg/L for the “physiological”
and 0.22 6 0.07 lg/L during the “reverse” study; p 5
0.01).
Diurnal rhythm of GH secretion was assessed using
1n transformed AUC data for 4h blocks (Fig. 4). Statis-
tically significant increases in AUC were observed be-
tween midnight and 0400 hours in the “reverse” (p 5
0.015) and “continuous” (p 5 0.01) cortisol infusion se-
ries. GH AUC were at their highest at the same time
during the “physiological” and baseline series, but only
statistical trends were apparent (p 5 0.12 and 0.06
respectively). The magnitude of these elevations were
similar in all series, with the absolute increase in the 1n
(AUC) between the lowest and the highest blocks be-
ing 1.3 for the baseline, 1.4 for the “continuous”, 1.1 for
the “physiological” and 0.8 for the “reverse” series. A
change of 0.7 in 1n (AUC) is equivalent to a doubling of
the AUC.
Fig. 1. Mean plasma cortisol concentrations during various
stages of the protocol. The data for the baseline and the “con-
tinuous” series are shown in the upper panel and for the
“physiological” and the “reverse” series, in the lower panel. SE
bars are omitted for clarity of presentation.
Fig. 2. Plasma GH concentrations in 2 patients during vari-
ous stages of the protocol
Fig. 3. Discrete parameters of GH pulsatility during various
stages of the protocol. *p , 0.02 vs. basal (saline infusion)
Fig. 4. Circadian rhythmicity of GH concentrations during
various stages of the protocol. Data are shown as mean of 1n
(AUC) of 4h blocks. *p , 0.02 vs. other daily blocks. For de-
tails see Results.
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Discussion
This is the first study to evaluate spontaneous GH
secretion in patients with Addison’s disease with and
without hydrocortisone replacement in a physiological
daily dose. Since each subject was used as his/her own
control, the potential influence of other variables, such
as body composition, age, gender and use of other
medications potentially affecting GH secretion (estro-
gen, thyroxine) was minimized. In the same patient
population, significant changes in the magnitude and
the pattern of TSH secretion were observed [12]. Thus,
the duration of cortisol deprivation and the variability
of plasma cortisol patterns were biologically meaning-
ful. Therefore, this model is likely  to shed  light on
glucocorticoid/GH interactions as well.
Virtually all studies addressing the issue of gluco-
corticoid effects upon GH secretion find that the states
of endogenous [6] or exogenous [7] glucocorticoid ex-
cess are accompanied by the suppression of GH output.
Thus, we expected that hydrocortisone infusions in pa-
tients with Addison’s disease would also result in a
lowering of mean 24 hour GH concentrations. Surpris-
ingly, the reverse was true: GH ouput doubled during
hydrocortisone administration compared to the base-
line study. This was due to the doubling of the GH pulse
amplitude and, to a lesser degree, to the tripling of the
interpulse GH concentrations. This constellation of
changes in the parameters of GH pulsatility is compat-
ible with the decreased hypothalamic SRIF release
[15]. Generally, it is assumed that glucocorticoids in-
hibit GHRH and stimulate SRIF secretion by the hy-
pothalamus [1,2]. These conclusions, however, are
based on experimental models utilizing supraphysi-
ologic  concentrations of glucocorticoids. In contrast,
cortisol concentrations in our study were carefully
maintained within a physiological range. In this re-
gard, the study by Fernandez-Vazquez et al. [16] is
very instructive and likely provides an explanation to
the dichotomy between our and other studies. They
have shown that the effects of corticosterone upon syn-
thesis and secretion of GHRH and SRIF by cultured
fetal rat hypothalamic cells are dose dependent. Corti-
costerone concentrations in the range of the glucocor-
ticoid receptor Kd (3nM) increased while higher con-
centrations (30 or 300 nM) decreased, GHRH content
and release. Similarly, corticosterone at 3nM did not
affect SRIF release, but higher concentrations (30 and
300 nM) induced doubling to tripling of SRIF release.
These data are fully compatible with our results, un-
derscoring the important distinction between physi-
ological and pharmacological glucocorticoid doses. We
show that physiological concentrations of cortisol are
stimulatory for GH secretion. Part of this effect might
have also been expressed directly at the pituitary
level, augmenting GH synthesis [4] and up-regulating
GHRH receptors [3]. Indeed, glucocorticoids are indis-
pensable for the full expression of the GH secretory
potential of cultured human [17], monkey [18] and rat
[5] pituitaries, as well as clonal cell lines of rat pituitary
tumors [19]. Interestingly, acute administration of
pharmacological doses of dexamethasone (4 mg i.v.) has
been recently shown to elicit a marked GH release in
humans [20,21]. On the other hand, physiological or
only slightly supraphysiological doses of hydrocorti-
sone inhibited (rather than stimulated) GH responses
to GHRH in patients with Addison’s disease [10]. Thus,
the stimulatory effects of hydrocortisone upon GH
pulse amplitude observed in our study are unlikely to
be due to a direct pituitary effect of the steroid. By
inference, the hypothalamic (SRIF suppression) ef-
fects of physiologic cortisol levels seem to provide a
better and, likely, sufficient physiological basis for our
results. Giustina et al. [22,23] have shown that hexare-
lin, a GH-secretagogue acting as a GHRH releaser and
a functional SRIF antagonist is able to counteract the
inhibitory effect of high glucocorticoid concentrations
upon GH secretion in humans. These data are in full
agreement with our interpretation of results.
We also tested the hypothesis that circadian GH
rhythm is glucocorticoid-driven, similarly to the re-
cently described effect of cortisol upon TSH secretion
[12]. However, even after 48–72h of cortisol depriva-
tion, the circadian rhythm of GH secretion still persist-
ed and was not modified by the non-physiological “con-
tinuous” and “reverse” cortisol infusions. It is
conceivable that a longer period of cortisol deprivation
may be needed to abolish the diurnal pattern of GH
secretion. However, prolongation of the glucocorticoid
“wash-out” period in patients with adrenal insuffi-
ciency may precipitate Addisonian crisis; such a study
would be unacceptable on ethical grounds. Impor-
tantly, the same duration of glucocorticoid deprivation
was sufficient to abolish the nocturnal TSH rise [12].
Thus, we believe that the persistence of the circadian
GH rhythm off glucocorticoids and the lack of effect of
antiphysiologic cortisol rhythms upon GH periodicity
disprove our original hypothesis and provide sufficient
evidence against a potential role of cortisol rhythmicity
upon circadian GH release.
In summary, we present the first evidence of the
stimulatory role of physiologic levels of cortisol upon
spontaneous GH secretion in patients with Addison’s
disease. This is likely to be mediated through inhibition
of hypothalamic SRIF secretion. On the other hand,
neither cortisol deprivation nor different modes of its
replacement have any effect upon circadian GH rhyth-
micity. Thus the mechanism(s) subserving the noctur-
nal augmentation of GH release are glucocorticoid in-
dependent.
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